Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint

End of Phase 2 Meeting Scheduled for HDV in February 2018 Phase 2 Readouts for PBH and Lymphedema in Second Half 2018 PALO ALTO, Calif., Jan. 16, 2018 -- (Healthcare Sales & Marketing Network) -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focuse... Biopharmaceuticals Eiger BioPharmaceuticals, pulmonary arterial hypertension, ubenimex
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news